Development and implementation of a multicentric pilot programme for lung cancer screening

ational Cancer Control Programme (PRONACCAN) of Uruguay0 个研究点目标入组 1,000 人开始时间: 2024年5月2日最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•1. Availability of written informed consent
•2. Aged 50 to 74 years
•3. 5-year lung cancer risk of at least 1.51% (using the Lung Cancer Risk Assessment Tool)
•4. No advanced chronic lung diseases
•5. No advanced occupational hazard conditions
•6. A clinical-functional status allowing the possibility to administer surgical treatment

•1. Second primaries of synchronous and metachronous cancer of both lungs or a combination of lung cancer with cancer of other organs excluding uterine cervix cancer, non-melanoma skin cancer, and lower lip cancer radically treated at least 3 years ago
•2. Previous treatment for lung cancer
•3. Acute tuberculosis
•4. Myocardial infarction, stroke in the case history in the course of the past 6 months before enrolling in the study
•Criteria for excluding from the study, based on examination findings:
•1. Congestive heart failure, class III or IV according to New York Heart Association (NYHA) classification, unrelated to the neoplastic process
•2. Uncontrolled severe hypertension or hypertension with systolic pressure >180 mmHg and/or diastolic pressure >110 mmHg, or orthostatic hypotension
•3. A positive test for human immunodeficiency virus (HIV), B or C hepatitis, or lues
•4. Mental diseases
•5. Chronic alcohol addiction
•6. Surd mutism
•Administrative causes for exclusion from the study:
•1. Kinship relations between the patient and the Centre’s employers
•2. The inability of visits/procedure performance and regular medical check-ups
•3. Refusal to undergo examination or treatment in the course of the study

发起方

ational Cancer Control Programme (PRONACCAN) of Uruguay